REG - Genus - Preliminary Results <Origin Href="QuoteRef">GENS.L</Origin> - Part 2
08/09/2015 07:01
- Part 2: For the preceding part double click ID:nRSH3388Ya
How We Manage Risk Risk Change in FY15
Protecting Intellectual Property· Genus-developed genetic material, methods and technology could become freely available to third parties We have a global, cross-functional process to identify and protect our IP. Our customer contracts and Unchanged
our selection of multipliers and joint venture partners include appropriate measures to protect our
IP. We conduct robust 'Freedom To Operate' searches to identify third-party rights to technology.
Ensuring Biosecurity and Continuity of Supply· Loss of key livestock, owing to disease outbreak· Loss of ability to move animals or semen freely (including across borders) due to disease outbreak, environmental incident or international trade sanctions· Industry-wide disease outbreaks affecting demand for Genus products We have stringent biosecurity standards, with independent reviews throughout the year to ensure Reduced We continued to strengthen our health management and supply chain resilience. The risks associated with the 2014/15 outbreak of PEDv in North America have been significantly mitigated.
compliance. We continue to extend the geographical diversity of our production facilities, to avoid
over-reliance on single sites.
Financial Risks
Risk Description How We Manage Risk Risk Change in FY15
Managing Agricultural Market and Commodity Prices Volatility· Fluctuations in agricultural markets affect customer profitability and therefore demand for our products and services· Increase in our operating costs, due to commodity pricing volatility We continuously monitor markets and seek to balance our costs and resources in response to market Unchanged
demand. We actively monitor and update our hedging strategy to manage our exposure. Our porcine
royalty model and extensive use of third party multipliers mitigates the impact of cyclical price
reductions or cost increases in pig production.
Funding Pensions· Exposure to costs associated with failure of third-party members of joint and several liabilities pension scheme· Exposure to costs as a result of external factors (such as mortality rates, interest rates or investment values) affecting the size of the pension deficit We are the principal employer for the Milk Pension Fund and chair the group of participating Unchanged
employers. The fund is now closed to future service and has an agreed deficit recovery plan, based on
the 2012 actuarial valuation. The result of the 2015 triennial actuarial valuation is due in late
2015. We monitor the strengths of other employers in the fund and have retained external consultants
to provide expert advice.
Group Income Statement Genus plc
For the year ended 30 June 2015
Note 2015£m 2014£m
REVENUE FROM CONTINUING OPERATIONS 2 398.5 372.2
ADJUSTED OPERATING PROFIT FROM CONTINUING OPERATIONS 2 47.2 42.9
Net IAS 41 valuation movement on biological assets 9 24.9 7.5
Amortisation of acquired intangible assets 8 (6.1) (5.8)
Share-based payment expense (1.4) (0.8)
64.6 43.8
Exceptional items
- Acquisition and integration 3 (1.4) (1.8)
- Other (including restructuring) 3 (4.1) (0.2)
- Pension related 3 0.4 -
(5.1) (2.0)
OPERATING PROFIT FROM CONTINUING OPERATIONS 59.5 41.8
Share of post-tax profit of joint ventures and associates 2.9 1.9
Net finance costs 4 (4.6) (5.5)
PROFIT BEFORE TAX FROM CONTINUING OPERATIONS 57.8 38.2
Taxation 5 (17.3) (9.3)
PROFIT FOR THE YEAR FROM CONTINUING OPERATIONS 40.5 28.9
ATTRIBUTABLE TO:
Owners of the Company 39.9 28.9
Non-controlling interest 0.6 -
40.5 28.9
EARNINGS PER SHARE FROM CONTINUING OPERATIONS 7
Basic earnings per share 66.7p 47.7p
Diluted earnings per share 65.9p 47.6p
NON-STATUTORY MEASURE OF PROFIT
Adjusted operating profit from continuing operations 47.2 42.9
Operating profit attributable to non-controlling interest (0.6) -
Pre-tax share of profits from joint ventures and associates excluding net IAS 41 valuation movement 4.6 1.9
ADJUSTED OPERATING PROFIT INCLUDING JOINT VENTURES AND ASSOCIATES 51.2 44.8
Net finance costs 4 (4.6) (5.5)
ADJUSTED PROFIT BEFORE TAX FROM CONTINUING OPERATIONS 46.6 39.3
ADJUSTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS 7
Basic adjusted earnings per share 56.8p 46.5p
Diluted adjusted earnings per share 56.1p 46.4p
Group Statement of Comprehensive Income Genus plc
For the year ended 30 June 2015
Note 2015£m 2015£m 2014£m 2014£m
PROFIT FOR THE YEAR 40.5 28.9
Items that may be reclassified subsequently to profit or loss
Foreign exchange translation differences 14.5 (53.9)
Fair value movement on net investment hedges (6.1) 8.6
Fair value movement on cash flow hedges - 0.3
Tax relating to components of other comprehensive income 5 (6.7) 7.8
1.7 (37.2)
Items that may not be reclassified subsequently to profit or loss
Actuarial (loss)/gain on retirement benefit obligations (8.5) 4.5
Tax relating to components of other comprehensive income 5 1.6 (2.5)
(6.9) 2.0
OTHER COMPREHENSIVE EXPENSE FOR THE YEAR (5.2) (35.2)
TOTAL COMPREHENSIVE INCOME/(EXPENSE) FOR THE YEAR 35.3 (6.3)
ATTRIBUTABLE TO:
Owners of the Company 35.0 (6.3)
Non-controlling interest 0.3 -
35.3 (6.3)
Group Statement of Changes in Equity Genus plc
Note Called up share capital£m Share premium account£m Own shares£m Trans-lation reserve£m Hedging reserve£m Retained earnings£m Total£m Non controlling interest£m Total equity£m
BALANCE AT 30 JUNE 2013 6.1 112.1 (0.1) 25.4 (0.3) 156.9 300.1 0.4 300.5
Foreign exchange translationdifferences, net of tax - - - (44.2) - - (44.2) - (44.2)
Fair value movement on net investment hedges, net of tax - - - 6.7 - - 6.7 - 6.7
Fair value movement on cashflow hedges, net of tax - - - - 0.3 - 0.3 - 0.3
Actuarial gain on retirement benefit obligations, net of tax - - - - - 2.0 2.0 - 2.0
Other comprehensive income/(expense) for the year - - - (37.5) 0.3 2.0 (35.2) - (35.2)
Profit for the year* - - - - - 28.9 28.9 - 28.9
Total comprehensive income for the year - - - (37.5) 0.3 30.9 (6.3) - (6.3)
Recognition of share-based payments, net of tax - - - - - 0.9 0.9 - 0.9
Issue of ordinary shares - 0.1 - - - - 0.1 - 0.1
Non-controlling interest on acquisition - - - - - - - 0.2 0.2
Dividends 6 - - - - - (10.1) (10.1) - (10.1)
BALANCE AT 30 JUNE 2014 6.1 112.2 (0.1) (12.1) - 178.6 284.7 0.6 285.3
Foreign exchange translationdifferences, net of tax - - - 6.8 - - 6.8 (0.3) 6.5
Fair value movement on net investment hedges, net of tax - - - (4.8) - - (4.8) - (4.8)
Actuarial loss on retirement benefit obligations, net of tax - - - - - (6.9) (6.9) - (6.9)
Other comprehensive (expense)/income for the year - - - 2.0 - (6.9) (4.9) (0.3) (5.2)
Profit for the year - - - - - 39.9 39.9 0.6 40.5
Total comprehensiveincome for the year - - - 2.0 - 33.0 35.0 0.3 35.3
Recognition of share-based payments, net of tax - - - - - 2.2 2.2 - 2.2
Adjustment arising from change in non controlling interest and written put option - - - - - - - (6.6) (6.6)
Dividends 6 - - - - - (11.1) (11.1) - (11.1)
BALANCE AT 30 JUNE 2015 6.1 112.2 (0.1) (10.1) - 202.7 310.8 (5.7) 305.1
Group Balance Sheet Genus plc
As at 30 June 2015
Note 2015£m 2014
£m
ASSETS
Goodwill 8 73.9 69.9
Other intangible assets 8 69.8 64.4
Biological assets 9 242.7 208.9
Property, plant and equipment 50.3 40.6
Interests in joint ventures and associates 19.6 21.7
Available for sale investments 0.2 0.1
Deferred tax assets 7.8 4.8
TOTAL NON-CURRENT ASSETS 464.3 410.4
Inventories 32.2 30.6
Biological assets 9 50.2 44.1
Trade and other receivables 10 74.7 75.1
Cash and cash equivalents 21.3 22.8
Income tax receivable 0.4 0.4
Derivative financial asset 0.7 -
Asset held for sale 0.5 0.8
TOTAL CURRENT ASSETS 180.0 173.8
TOTAL ASSETS 644.3 584.2
LIABILITIES
Trade and other payables (58.9) (53.3)
Interest-bearing loans and borrowings (12.2) (13.0)
Provisions (2.4) (1.4)
Obligations under finance leases (1.1) (1.1)
Current tax liabilities (6.3) (6.4)
Derivative financial liabilities (0.2) (2.6)
TOTAL CURRENT LIABILITIES (81.1) (77.8)
Interest-bearing loans and borrowings (77.4) (71.1)
Retirement benefit obligations 11 (63.1) (58.2)
Deferred tax liabilities (105.2) (90.3)
Derivative financial liabilities (10.0) -
Obligations under finance leases (2.4) (1.5)
TOTAL NON-CURRENT LIABILITIES (258.1) (221.1)
TOTAL LIABILITIES (339.2) (298.9)
NET ASSETS 305.1 285.3
2015£m 2014
£m
EQUITY
Called up share capital 6.1 6.1
Share premium account 112.2 112.2
Own shares (0.1) (0.1)
Translation reserve (10.1) (12.1)
Hedging reserve - -
Retained earnings 202.7 178.6
Equity attributable to owners of the Company 310.8 284.7
Non-controlling interest 4.3 0.6
Put option over non-controlling interests (10.0) -
Total non-controlling interests (5.7) 0.6
Total equity 305.1 285.3
Group Statement of Cash Flows Genus plc
For the year ended 30 June 2015
Note 2015£m 2014£m
NET CASH FLOW FROM OPERATING ACTIVITIES 12 34.8 32.3
CASH FLOWS FROM INVESTING ACTIVITIES
Dividends received from joint ventures and associates 2.3 0.9
Acquisition of subsidiaries 14 (10.3) (20.9)
Purchase of trade and assets - (2.0)
Acquisition of investment in joint venture (0.8) (11.2)
Purchase of property, plant and equipment (12.0) (5.1)
Purchase of intangible assets (2.8) (1.5)
Proceeds from sale of property, plant and equipment 0.3 -
Proceeds from sale of assets held for sale - 0.3
NET CASH OUTFLOW FROM INVESTING ACTIVITIES (23.3) (39.5)
CASH FLOWS FROM FINANCING ACTIVITIES
Drawdown of borrowings 51.8 48.0
Repayment of borrowings (51.0) (29.2)
Payment of finance lease liabilities (1.5) (1.4)
Equity dividends paid (11.1) (10.1)
Issue of ordinary shares - 0.1
Debt issue costs - (0.8)
(Decrease)/increase in bank overdrafts (2.0) 6.4
NET CASH (OUTFLOW)/INFLOW FROM FINANCING ACTIVITIES (13.8) 13.0
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS (2.3) 5.8
Cash and cash equivalents at start of the year 22.8 18.4
Net (decrease)/increase in cash and cash equivalents (2.3) 5.8
Cash acquired on acquisition 1.5 0.4
Effect of exchange rate fluctuations on cash and cash equivalents (0.7) (1.8)
TOTAL CASH AND CASH EQUIVALENTS AT 30 JUNE 21.3 22.8
Notes to the Preliminary Results Genus plc
For the year ended 30 June 2015
1. REPORTING ENTITY
Status of audit
The financial information given does not constitute the Company's statutory accounts for the year ended 30 June 2015 or the
year ended 30 June 2014, but is derived from those accounts. Statutory accounts for the year ended 30 June 2014 have been
delivered to the Registrar of Companies and those for the year ended 30 June 2015 will be delivered following the Company's
annual general meeting. The auditors have reported on those accounts; their reports were unqualified, did not draw
attention to any matters by way of emphasis without qualifying their reports, and did not contain statements under s.
498(2) or (3) Companies Act 2006.
Basis of preparation
The financial information for the year ended 30 June 2015 together with the comparative year has been computed in
accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union.
The Group Financial Statements are presented in Sterling, which is the Company's functional and presentation currency. All
financial information presented in Sterling has been rounded to the nearest million at one decimal point.
The principal exchange rates were as follows:
Average Closing
2015 2014 2013 2015 2014 2013
US Dollar/£ 1.57 1.64 1.57 1.57 1.71 1.52
Euro/£ 1.32 1.20 1.21 1.41 1.25 1.17
Brazilian Real/£ 4.26 3.75 3.22 4.89 3.77 3.35
Mexican Peso/£ 22.68 21.44 20.16 24.68 22.18 19.76
While the financial information included in this preliminary announcement has been computed in accordance with IFRSs, this
announcement does not itself contain sufficient information to comply with IFRSs. The Company expects to publish full
financial statements that comply with IFRSs in October 2015. These financial statements have also been prepared in
accordance with the accounting policies set out in the 2014 Annual Report and Financial Statements, as amended by the
following new accounting standards.
New standards and interpretations
The following new standards and interpretation have been adopted in the current period:
· 'Improvements to IFRS 2010-2012 cycle';
· 'Improvements to IFRS 2011-2013 cycle';
· IFRIC 21 'Levies'; and
· Amendments to 'Offsetting Financial Assets and Financial Liabilities' (IAS 32), 'Investment Entities' (IFRS
10,
IFRS 12 and IAS 27), 'Recoverable Amounts Disclosures for Non-Financial Assets' (IAS 36), 'Novation of
Derivatives and Continuation of Hedge Accounting' (IAS 39), 'Defined Benefit Plans: Employee
Contributions' (IAS 19).
There has been no significant impact on the results or disclosures for the current period from the adoption of these new
standards and interpretations.
At the date of authorisation of these Group Financial Statements, the following standards and interpretations which have
not been applied in preparing these Group Financial Statements were in issue but not yet effective (and in some cases had
not yet been adopted by the EU):
· IFRS 9 'Financial Instruments';
· IFRS 14 'Regulatory Deferral Response'; and
· IFRS 15 'Revenue from Contracts with Customers'.
The Directors anticipate that the adoption of these standards and interpretations in future periods will have no material
impact on the financial statements of the Group, except as follows:
· IFRS 9 'Financial Instruments', which will introduce a number of changes in the presentation of financial
instruments.
Beyond the information above, it is not practicable to provide a reasonable estimate of the effect of these standards until
a detailed review has been completed.
Going concern
After reviewing the available information including the Group's business plans and after making enquiries, the Directors
have a reasonable expectation that the Group has adequate resources to continue in operational existence for the
foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial
statements.
At 30 June 2015 the Group had net debt of £71.8m (2014: £63.9m) and undrawn committed borrowing facilities of £51.1m. The
Group's credit facilities at the balance sheet date comprised a £65m multi-currency revolving credit facility, a US$100m
revolving credit facility and an amortising US$15m term loan, repayable in instalments by 15 September 2017. We do not
expect the financial covenants on these facilities to prevent the Group making further use of the facilities if required.
This, together with the maturity profile of debt, gives the Directors confidence that the Group has sufficient financial
resources for the foreseeable future. As a consequence, the Directors believe that the Company is well placed to manage
its business despite current uncertainties in the economic environment.
Non-GAAP measures - adjusted operating profit, adjusted profit before tax and adjusted earnings per share
Adjusted operating profit, adjusted operating profit before tax from continuing operations and adjusted earnings per share
exclude the net IAS 41 valuation movement on biological assets, amortisation of acquired intangible assets, share-based
payment expense, exceptional items and other gains and losses.
We believe these non-GAAP measures provide shareholders with useful information about the Group's trading performance. The
reconciliation between operating profit from continuing operations and adjusted operating profit from continuing operations
is shown on the face of the Group Income Statement.
This preliminary announcement was approved by the Board on 7 September 2015
2. SEGMENTAL INFORMATION
The Group presents its segmental information on the basis that the chief operating decision maker regularly reviews for
assessing our business performance and allocating resources.
Our business is not highly seasonal and our customer base is diversified, with no individual customer generating more than
2% of revenue.
Revenue
2015 2014
£m £m
Genus PIC 175.5 152.8
Genus ABS 167.8 157.4
Genus Asia 41.4 46.5
Research and Development
Research - -
Porcine Product Development 13.8 15.5
Bovine Product Development - -
13.8 15.5
398.5 372.2
Operating profit by segment is set out below and reconciled to the Group's adjusted operating profit. A reconciliation of
adjusted operating profit to profit for the year is shown on the Group Income Statement.
Operating profit
2015 2014
£m £m
Genus PIC 57.2 49.9
Genus ABS 24.0 24.3
Genus Asia 5.7 6.8
Research and Development
Research (4.6) (3.6)
Porcine Product Development (11.6) (12.5)
Bovine Product Development (12.4) (11.6)
(28.6) (27.7)
Segment operating profit 58.3 53.3
Central costs (11.1) (10.4)
Adjusted operating profit 47.2 42.9
Other segment information
Depreciation Amortisation Additions to non-current assets
2015£m 2014£m 2015£m 2014£m 2015£m 2014£m
Genus PIC 0.5 0.4 6.1 5.8 0.5 0.5
Genus ABS 1.5 1.2 0.6 0.6 1.8 1.9
Genus Asia 0.5 0.4 - 0.4 0.3
Research and Development
Research 0.1 - - - 5.2 0.2
Porcine Product Development 1.9 1.7 - - 0.6 0.7
Bovine Product Development 0.2 0.1 - - 5.2 2.5
2.2 1.8 - - 11.0 3.4
Segment total 4.7 3.8 6.7 6.4 13.7 6.1
Central 1.6 1.3 - - 3.3 1.7
Total 6.3 5.1 6.7 6.4 17.0 7.8
Segment assets Segment liabilities
2015£m 2014£m 2015£m 2014£m
Genus PIC 194.9 198.6 (45.5) (41.4)
Genus ABS 123.7 107.3 (39.9) (32.5)
Genus Asia 37.0 38.6 (7.6) (7.7)
Research and Development
Research 6.0 1.2 (0.1) (0.8)
Porcine Product Development 110.0 86.1 (47.6) (35.0)
Bovine Product Development 167.5 149.0 (52.2) (45.9)
283.5 236.3 (99.9) (81.7)
Segment total 639.1 580.8 (192.9) (163.3)
Central 5.2 3.4 (146.3) (135.6)
Total 644.3 584.2 (339.2) (298.9)
Other exceptional items of £5.1m expense (2014: £2.0m), relate to Genus PIC (£1.5m), Genus ABS (£0.9m) Genus Asia (£0.1m),
Research and Development (£2.8m) and our central segment (£0.2m credit). Note 3 provides details of these exceptional
items.
We consider share-based payments on a Group-wide basis and do not allocate them to reportable segments.
Geographical information
The Group's revenue by geographical segments is analysed below:
Revenue
2015 2014
£m £m
North America 181.2 153.7
Latin America 59.0 50.2
Europe, Middle East and Africa 116.9 121.8
Asia 41.4 46.5
398.5 372.2
Non-current assets (excluding deferred taxation and financial instruments)
2015£m 2014£m
North America 306.3 261.2
Latin America 51.2 45.2
Europe, Middle East and Africa 85.0 84.8
Asia 14.0 14.4
456.5 405.6
Revenue by type 2015£m 2014£m
Sale of animals, semen and associated products and services 314.4 297.7
Royalties 77.1 67.1
Consulting services 7.0 7.4
398.5 372.2
Interest income (see note 10) 0.2 0.2
Total 398.7 372.4
3. EXCEPTIONAL ITEMS
Operating (expenses)/income: 2015£m 2014£m
Acquisition and integration (1.4) (1.8)
Legal fees (2.8) (0.6)
Other (including restructuring) (1.3) 0.4
Pension related 0.4 -
(5.1) (2.0)
During the period, £1.4m of expenses were incurred in relation to the acquisition and integration, principally in relation
to Birchwood and In Vitro Brasil S.A., of £0.3m and £0.9m, respectively. See note 14.
Legal fees of £2.8m (2014: £0.6m) related to an action by ABS Global Inc. against Inguran LLC (aka Sexing Technologies).
On 14 July 2014, ABS Global, Inc. ('ABS'), a wholly owned subsidiary of the Company, launched a legal action against
Inguran, LLC (aka Sexing Technologies ('ST')), in the US District Court for the Western District of Wisconsin alleging,
among other matters, that ST (i) have a monopoly in the processing of sexed bovine semen in the US and (ii) unlawfully
maintain this monopoly through anticompetitive contractual provisions and the repeated acquisition of exclusive patent
rights related to semen processing. The legal action aims to remove these barriers and allow free and fair competition in
the sexed bovine semen processing market ('ABS Action'). On the same date, ABS also filed an Inter-Partes Review
application ('IPR') challenging the validity of one of the ST's group patents, US Patent No. 7,195,920 (the '920 patent')
before the US Patent Office. Subsequently, ABS also filed IPRs challenging the validity of ST's group patents US Patent No.
7,820,425 (the '425 patent') and US Patent No. 8,206,987 (the '987 patent').
On 7 November 2014, ST filed its Answer and Counterclaim to the ABS Action, denying any anticompetitive activities, and
alleging, among other matters, (i) that ABS fraudulently induced ST to enter into the parties' semen sorting agreement,
(ii) that the Company and ABS repudiated and breached the agreement, and (iii) that the Company and ABS have infringed the
'987 patent.
On 13 January 2015 and 15 April 2015 respectively, the Patent Trial and Appeal Board ('PTAB') ruled that ABS had
demonstrated a reasonable likelihood of prevailing on its assertion that relevant claims of the '920 patent and the '425
patent were invalid, and ordered the institution of a trial.
On 31 March 2015, the Court in Wisconsin, among other matters (i) denied ST's motion to transfer the ABS Action to Texas,
confirming that Wisconsin was the appropriate venue, (ii) denied ST's partial motion to dismiss the ABS Action, and (iii)
permitted XY Inc. ('XY'), a subsidiary of ST, to join the litigation. Subsequently, a revised timetable for the ABS Action
was established, and the trial is now scheduled to commence on 1 August 2016.
On 6 May, 2015 XY filed an Answer and Counterclaim denying the anti-competitive activities and alleging, among other
matters, infringement of the '920 patent and the '425 patent by both ABS and the Company.
On 29 April 2015, the PTAB ruled that ABS had not demonstrated a reasonable likelihood of prevailing on its assertion that
relevant claims of the '987 patent were invalid and declined to order the institution of a trial. ABS will now pursue the
invalidity of this patent through the Wisconsin litigation.
On 12 June 2015, ST was given leave to amend its counterclaims to allege the infringement by ABS and the Company of US
Patent No. 8,198,092 (the '092 patent').
This Wisconsin litigation continues through discovery, depositions and related preparations for trial. ABS intends to
continue to vigorously pursue this litigation, in order to seek to enter and compete in this market using its own
technology.
Included within other is £1.2m related principally to refocus the European porcine business as it continues to reduce farm
operations and align with the Group's global strategy.
During the year a settlement gain of £0.4m was recorded in relation to members leaving the Milk Pension Fund.
4. NET FINANCE COSTS
2015£m 2014£m
Interest payable on bank loans and overdrafts (1.8) (1.7)
Amortisation of debt issue costs (0.4) (0.4)
Other interest payable (0.1) (0.2)
Net interest cost in respect of pension scheme liabilities (2.3) (2.9)
Net interest cost on derivative financial instruments (0.2) (0.5)
Total interest expense (4.8) (5.7)
Interest income on bank deposits 0.2 0.2
Total interest income 0.2 0.2
Net finance costs (4.6) (5.5)
5. INCOME TAX EXPENSE
2015£m 2014£m
Current tax expense
Current period 13.0 10.8
Adjustment for prior periods (0.4) (0.7)
Total current tax expense in the Group Income Statement 12.6 10.1
Deferred tax expense/(income)
Origination and reversal of temporary differences 5.1 (1.0)
Adjustment for prior periods (0.4) 0.2
Total deferred tax expense/(income) in the Group Income Statement 4.7 (0.8)
Total income tax expense excluding share of income tax of equity accounted investees 17.3 9.3
Share of income tax of equity accounted investees 0.7 0.7
Total income tax expense in the
- More to follow, for following part double click ID:nRSH3388YcRecent news on Genus
See all newsREG - Genus PLC - Director/PDMR Shareholding
AnnouncementREG - Genus PLC - Interim Results
AnnouncementREG - Genus PLC - Block Listing Return
AnnouncementREG - Genus PLC - Total Voting Rights
AnnouncementREG - Genus PLC - Successful formation of Chinese porcine JV
Announcement